Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Breast Cancer
Gastric Cancer
Non-small Cell Lung Cancer
Cervical Cancer
Endocervical Cancer
Squamous Cell Carcinoma of Head and Neck
Bladder Urothelial Cancer
Colorectal Carcinoma
Esophageal Cancer
Ovarian Cancer
Renal Cell Carcinoma
Prostate Cancer
Melanoma
Mesothelioma
Cholangiocarcinoma

Interventions

DRUG: NGM831
DRUG: NGM831 plus pembrolizumab (KEYTRUDA®)
DRUG: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)

Sponsor

NGM Biopharmaceuticals, Inc

Collaborators

[object Object]